Loading clinical trials...
Loading clinical trials...
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)
Conditions
Interventions
Benralizumab
Placebo
Locations
39
United States
Research Site
Phoenix, Arizona, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Centennial, Colorado, United States
Research Site
Margate, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Beverly, Massachusetts, United States
Start Date
March 31, 2021
Primary Completion Date
October 26, 2023
Completion Date
October 26, 2023
Last Updated
November 29, 2024
NCT06371417
NCT02753777
NCT05906706
NCT04563923
NCT04117932
NCT01265082
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions